{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:24Z","timestamp":1794047484806,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm for multiple B-cell malignancies, including follicular lymphoma. Two CD20xCD3 bispecific antibodies, mosunetuzumab and epcoritamab, are now approved in the United States for third-line or later treatment of follicular lymphoma. A third agent, odronextamab, remains under review by regulatory agencies. In pivotal phase II trials, these bispecific antibodies demonstrated overall response rates of approximately 80%, with complete response rates of 60-70%, the majority of which have been durable at 2 years. Important safety signals included risk of infections, neutropenia, and cytokine release syndrome, which occurred in approximately half of patients, but was rarely high grade. Despite similar efficacy and toxicity profiles, key differences exist among agents, primarily relating to treatment duration, route of administration, and prophylactic corticosteroid use. Several ongoing studies are exploring bispecific antibodies in earlier lines of treatment, either as single agents or in combination with other active therapies. This novel class of agents is likely to play a pivotal role in improving outcomes for patients with follicular lymphoma.<\/jats:p>","DOI":"10.3324\/haematol.2024.285245","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:10:31Z","timestamp":1730347831000},"page":"1472-1482","source":"Crossref","is-referenced-by-count":10,"title":["Bispecific antibodies in follicular lymphoma"],"prefix":"10.3324","volume":"110","author":[{"given":"Imran A.","family":"Nizamuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"76145","doi-asserted-by":"crossref","unstructured":"Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985; 314(6012):628-631.","DOI":"10.1038\/314628a0"},{"key":"76146","doi-asserted-by":"crossref","unstructured":"Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions - improving antibodies for cancer treatment. Antibodies (Basel). 2020; 9(4):64.","DOI":"10.3390\/antib9040064"},{"key":"76147","doi-asserted-by":"crossref","unstructured":"Wang L, Hoseini SS, Xu H, Ponomarev V, Cheung NK. Silencing Fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency. Cancer Immunol Res. 2019; 7(12):2013-2024.","DOI":"10.1158\/2326-6066.CIR-19-0121"},{"key":"76148","doi-asserted-by":"crossref","unstructured":"Adams R, Griffin L, Compson JE. Extending the half-life of a Fab fragment through generation of a humanized anti-human serum albumin Fv domain: an investigation into the correlation between affinity and serum half-life. MAbs. 2016; 8(7):1336-1346.","DOI":"10.1080\/19420862.2016.1185581"},{"key":"76149","doi-asserted-by":"crossref","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015; 20(7):838-847.","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"76150","doi-asserted-by":"crossref","unstructured":"Haber L, Olson K, Kelly MP. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021; 11(1):14397.","DOI":"10.1038\/s41598-021-93842-0"},{"key":"76151","doi-asserted-by":"crossref","unstructured":"Hoffmann P, Hofmeister R, Brischwein K. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005; 115(1):98-104.","DOI":"10.1002\/ijc.20908"},{"key":"76152","doi-asserted-by":"crossref","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506.","DOI":"10.3324\/haematol.2019.243543"},{"key":"76153","doi-asserted-by":"crossref","unstructured":"Sun LL, Ellerman D, Mathieu M. Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7(287):287.","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"76154","doi-asserted-by":"crossref","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020; 52:102625.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"76155","doi-asserted-by":"crossref","unstructured":"Smith EJ, Olson K, Haber LJ. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015; 5(1):17943.","DOI":"10.1038\/srep17943"},{"key":"76156","doi-asserted-by":"crossref","unstructured":"Bacac M, Colombetti S, Herter S. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018; 24(19):4785-4797.","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"76157","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: extended follow-up of a phase I\/II study. J Clin Oncol. 2024; 42(19):2250-2256.","DOI":"10.1200\/JCO.23.02329"},{"key":"76158","doi-asserted-by":"crossref","unstructured":"Kim TM, Taszner M, Novelli S. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024; 35(11):1039-1047.","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"76159","doi-asserted-by":"crossref","unstructured":"Linton KM, Vitolo U, Jurczak W. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024; 11(8):e593-e605.","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"76160","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"76161","doi-asserted-by":"crossref","unstructured":"Budde LE, Sehn LH, Matasar M. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23(8):1055-1065.","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"76162","unstructured":"Assouline S, Bartlett NL, Matasar M. Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pretreated R\/R FL after \u22653 years of follow up: subgroup analysis of a pivotal phase II study. Hemasphere. 2024; 8(Supplement 1):288-289."},{"key":"76163","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Sehn LH, Bartlett NL. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study. Blood. 2023; 142(Supplement 1):603.","DOI":"10.1182\/blood-2023-173692"},{"key":"76164","doi-asserted-by":"crossref","unstructured":"Bartlett NL, Sehn LH, Matasar MJ. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study. Blood. 2022; 140(Supplement 1):1467-1470.","DOI":"10.1182\/blood-2022-157691"},{"key":"76165","doi-asserted-by":"crossref","unstructured":"Budde EL, Bartlett NL, Giri P. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study. Blood. 2022; 140(Supplement 1):3753-3755.","DOI":"10.1182\/blood-2022-157729"},{"key":"76166","doi-asserted-by":"crossref","unstructured":"van der Horst HJ, de Jonge AV, Hiemstra IH. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021; 11:38.","DOI":"10.1038\/s41408-021-00430-6"},{"key":"76167","doi-asserted-by":"crossref","unstructured":"Hutchings M, Mous R, Clausen MR. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021; 398(10306):1157-1169.","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"76168","doi-asserted-by":"crossref","unstructured":"Bannerji R, Arnason JE, Advani RH. Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5):e327-e339.","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"76169","doi-asserted-by":"crossref","unstructured":"Villasboas JC, Kim TM, Taszner M. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) with extended follow-up. Blood. 2023; 142(Supplement 1):3041.","DOI":"10.1182\/blood-2023-181650"},{"key":"76170","doi-asserted-by":"crossref","unstructured":"Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021; 39(18):1959-1970.","DOI":"10.1200\/JCO.20.03175"},{"key":"76171","doi-asserted-by":"crossref","unstructured":"Reynolds GK, Maclean M, Cliff ERS. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv. 2024; 8(13):3555-3559.","DOI":"10.1182\/bloodadvances.2024012916"},{"key":"76172","doi-asserted-by":"crossref","unstructured":"Crombie JL, Graff T, Falchi L. Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024; 143(16):1565-1575.","DOI":"10.1182\/blood.2023022432"},{"key":"76173","doi-asserted-by":"crossref","unstructured":"Lynch RC, Poh C, Shadman M. Early complete responses with mosunetuzumab monotherapy in treatment-na\u00efve follicular and marginal zone lymphomas with only low-grade cytokine release syndrome. Blood. 2023; 142(Supplement 1):4397.","DOI":"10.1182\/blood-2023-174292"},{"key":"76174","doi-asserted-by":"crossref","unstructured":"Falchi L, Okwali M, Ghione P. Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): first results of a multicenter phase 2 study. Blood. 2023; 142(Supplement 1):604.","DOI":"10.1182\/blood-2023-179906"},{"key":"76175","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Chavez JC, Sehgal AR. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23(1):91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"76176","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Dahiya S, Palomba ML. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024; 30(8):2199-2207.","DOI":"10.1038\/s41591-024-02986-9"},{"key":"76177","doi-asserted-by":"crossref","unstructured":"Crochet G, Iacoboni G, Couturier A. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024; 144(3):334-338.","DOI":"10.1182\/blood.2024024526"},{"key":"76178","doi-asserted-by":"crossref","unstructured":"Elsallab M, Ellithi M, Lunning MA. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood. 2024; 143(20):2099-2105.","DOI":"10.1182\/blood.2024024166"},{"key":"76179","doi-asserted-by":"crossref","unstructured":"Levine BL, Pasquini MC, Connolly JE. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024; 30(2):338-341.","DOI":"10.1038\/s41591-023-02767-w"},{"key":"76180","doi-asserted-by":"crossref","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023; 141(5):467-480.","DOI":"10.1182\/blood.2021011994"},{"key":"76181","doi-asserted-by":"crossref","unstructured":"Matasar M, Bartlett NL, Shadman M. Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial. Clin Lymphoma Myeloma Leuk. 2024; 24(4):240-253.","DOI":"10.1016\/j.clml.2023.12.005"},{"key":"76182","doi-asserted-by":"crossref","unstructured":"Lussana F, Gritti G, Rambaldi A. Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies. J Clin Oncol. 2021; 39(5):444-455.","DOI":"10.1200\/JCO.20.01564"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285245\/77735","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285245\/78508","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11806\/77735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:33Z","timestamp":1794046053000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285245","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}